POTOMAC, Md. (DC News Now) — There’s nothing quite like the 4×400-meter relay in track and field. “It takes very strong mental strength for sure,” said sophomore sprinter Cameron Homer. “You’re a ...
Barclays analyst Peter Lawson reiterated a Hold rating on Relay Therapeutics (RLAY – Research Report) yesterday and set a price target of $15.00. The company’s shares closed yesterday at $10.57.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results